China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II clinical study for its TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, ICP-488, in patients with moderate to severe plaque psoriasis.
ICP-488 is a potent and selective TYK2 allosteric inhibitor that is being developed to treat psoriasis and other autoimmune diseases. It works by blocking the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines by binding to the JH2 domain, thereby inhibiting the pathological process of autoimmune and inflammatory diseases.
The Phase II study, which was randomized, double-blinded, and placebo-controlled, aimed to assess the efficacy and safety of ICP-488 in patients with moderate to severe plaque psoriasis. The primary endpoint was a reduction of at least 75% in psoriasis area and severity index scores compared to baseline at week 12 (PASI 75). The study results indicated that patients who received 6 mg and 9 mg (once daily) ICP-488 showed significantly improved PASI 75 response rates at week 12 compared to the placebo group. Additionally, PASI 90, PASI 100, and static physicians’ global assessment (sPGA) 0/1 response rates were significantly higher in the ICP-488 groups than in the placebo group. The drug also demonstrated a favorable safety profile.- Flcube.com
